These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
363 related articles for article (PubMed ID: 19699248)
1. Design and development of polymer conjugates as anti-angiogenic agents. Segal E; Satchi-Fainaro R Adv Drug Deliv Rev; 2009 Nov; 61(13):1159-76. PubMed ID: 19699248 [TBL] [Abstract][Full Text] [Related]
2. Recent advances in tumor vasculature targeting using liposomal drug delivery systems. Abu Lila AS; Ishida T; Kiwada H Expert Opin Drug Deliv; 2009 Dec; 6(12):1297-309. PubMed ID: 19780711 [TBL] [Abstract][Full Text] [Related]
3. Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery. Bouzin C; Feron O Drug Resist Updat; 2007 Jun; 10(3):109-20. PubMed ID: 17452119 [TBL] [Abstract][Full Text] [Related]
4. Microtubule-targeting agents in angiogenesis: where do we stand? Pasquier E; Honoré S; Braguer D Drug Resist Updat; 2006; 9(1-2):74-86. PubMed ID: 16714139 [TBL] [Abstract][Full Text] [Related]
5. [Novel angiogenesis inhibitors for molecular target therapy of cancer]. Osada H; Kakeya H Nihon Rinsho; 2004 Jul; 62(7):1257-63. PubMed ID: 15283141 [TBL] [Abstract][Full Text] [Related]
6. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Maeda H; Bharate GY; Daruwalla J Eur J Pharm Biopharm; 2009 Mar; 71(3):409-19. PubMed ID: 19070661 [TBL] [Abstract][Full Text] [Related]
7. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
8. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Abdollahi A; Folkman J Drug Resist Updat; 2010; 13(1-2):16-28. PubMed ID: 20061178 [TBL] [Abstract][Full Text] [Related]
9. Potential role of vascular targeted therapy to combat against tumor. Chen B; Jin H; Wu K Expert Opin Drug Deliv; 2009 Jul; 6(7):719-26. PubMed ID: 19538038 [TBL] [Abstract][Full Text] [Related]
10. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Greco F; Vicent MJ Adv Drug Deliv Rev; 2009 Nov; 61(13):1203-13. PubMed ID: 19699247 [TBL] [Abstract][Full Text] [Related]
11. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer. Roukos DH; Tzakos A; Zografos G Expert Rev Anticancer Ther; 2009 Oct; 9(10):1413-6. PubMed ID: 19828000 [No Abstract] [Full Text] [Related]
12. Polymer-protein and polymer-drug conjugates in cancer therapy. Thanou M; Duncan R Curr Opin Investig Drugs; 2003 Jun; 4(6):701-9. PubMed ID: 12901229 [TBL] [Abstract][Full Text] [Related]
13. Mitochondria as targets in angiogenesis inhibition. Park D; Dilda PJ Mol Aspects Med; 2010 Feb; 31(1):113-31. PubMed ID: 19995570 [TBL] [Abstract][Full Text] [Related]
14. The role of angiogenesis in solid tumours: an overview. Makrilia N; Lappa T; Xyla V; Nikolaidis I; Syrigos K Eur J Intern Med; 2009 Nov; 20(7):663-71. PubMed ID: 19818284 [TBL] [Abstract][Full Text] [Related]
15. Anti-angiogenic therapies in cancer: achievements and open questions. Ruegg C; Mutter N Bull Cancer; 2007 Sep; 94(9):753-62. PubMed ID: 17878094 [TBL] [Abstract][Full Text] [Related]
16. The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy. van der Meel R; Symons MH; Kudernatsch R; Kok RJ; Schiffelers RM; Storm G; Gallagher WM; Byrne AT Drug Discov Today; 2011 Mar; 16(5-6):219-28. PubMed ID: 21262381 [TBL] [Abstract][Full Text] [Related]
17. Anti-angiogenic drugs: from bench to clinical trials. Quesada AR; Muñoz-Chápuli R; Medina MA Med Res Rev; 2006 Jul; 26(4):483-530. PubMed ID: 16652370 [TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms and therapeutic development of angiogenesis inhibitors. Cao Y Adv Cancer Res; 2008; 100():113-31. PubMed ID: 18620094 [TBL] [Abstract][Full Text] [Related]